

1 Dalmore Drive,
Scoresby,
Victoria 3179
AUSTRALIA
T: +61 (0)3 9763-1287
F: +61 (0)3 9763-2817
www.generabiosystems.com

Friday 23 October 2015

**ASX Announcement – GENERA BIOSYSTEMS LIMITED (ASX: GBI)
GENERA ESTABLISHES WORLD CLASS CLINICAL AND SCIENTIFIC ADVISORY BOARD**

Genera Biosystems Limited (**‘Genera’**) is pleased to advise that it has established a world class clinical and scientific advisory board with a particularly strong focus on human papilloma virus (HPV) screening. Members of the advisory board include Prof Jack Cuzick, Prof Cosette Wheeler, Prof Susan Garland and Associate Prof Sepehr Tabrizi.

Richard Hannebery, Genera Chief Executive Officer commented, “We are humbled by the caliber of individuals we have been able to attract to this very important board. To be able to not only pique the interest of the likes of Jack Cuzick and Cosette Wheeler in what we are doing with our PapType® HPV assay, but to secure their services in joining this advisory board in a formal capacity, gives us tremendous comfort that we are doing something right in our approach to the HPV screening market.

Genera’s PapType® HPV test which simultaneously detects and genotypes all 14 high-risk viral types of HPV received ARTG listing and CE mark earlier this year. Subsequent to these approvals Genera received summary clinical data from the 6,000 patient Predictors 3 study in a cervical cancer screening population from the Wolfson Institute of Preventive Medicine (London). While the data remains confidential at this stage, the company has previously advised that it is consistent with prior data generated by PapType® in the Predictors 2 study, a 1,099 patient study in an ASCUS population also undertaken by the Wolfson Institute.

Richard Hannebery added, “To secure the services of both Susan and Sepehr is also a significant coup for Genera. Both Susan and Sepehr have had a longstanding watching brief on PapType®, together with a more general interest in sexually transmitted infections that is highly relevant to our next assay targeting regulatory approval - STIplex™.

Bios of Genera’s new established Scientific and Clinical Advisory Board are provided below.

Professor Jack Cuzick Ph.D. FMedSci, FRCP (hon)

Professor Jack Cuzick is head of the Centre for Cancer Prevention in London, and John Snow Professor of Epidemiology at the Wolfson Institute of Preventive Medicine at Queen Mary, University of London. He holds a PhD in Mathematics and has previously worked at Oxford and Columbia Universities. Over the past three decades he has become a leading epidemiologist

working on screening and prevention of cancer. He is currently Chairman of the International Breast Cancer Intervention Study (IBIS) Steering Group, the Independent Statistician for the ATAC trial and is also involved in studies on the use of HPV assays for cervical screening, the use of flexible sigmoidoscopy for colorectal cancer screening and markers for the behaviour of early prostate cancer.

Professor Cuzick has also made valuable contributions to assessing the risk of developing breast cancer and to cancer screening, notably in cervix cancer. His widely disseminated position paper on the requirements for an effective screening program in 1986 led to major reorganisation of the UK programme, and resulted in dramatic falls in mortality, which he and his colleagues have closely monitored. He has also been the world leader in advocating HPV testing for primary screening.

In 2007, he was chosen by Thompson Scientific as one of the twelve hottest researchers in all of science and in 2012 he won American Association for Cancer Research (AACR) Cancer Prevention Prize, Jack is also the recipient of the EUROGIN award for distinguished service to cervix cancer and most recently in October 2015 Prof Cuzick was awarded the *Medal of Honour* - American Cancer Society's highest honour at their annual celebration dinner to recognise his three decades of leadership in cancer prevention and screening.

He is a past president of the International Society of Cancer Prevention, of which he is a founding member. He is a Fellow of the Academy of Medical Sciences, the Royal Statistical Society, the Institute of Mathematical Statistics and is an Honorary Fellow of the Royal College of Physicians of London.

Prof Cuzick is the author of more than 400 peer-reviewed papers and has published in all the major medical journals and his numerous papers remain among the most cited by cancer researchers worldwide.

Professor Cosette Wheeler Ph.D.

Professor Cosette Wheeler, Ph.D., is a University of New Mexico Regents Professor in both the Department of Pathology and the department of Obstetrics and Gynecology. Over more than 20 years she and her research group have published over 150 peer-reviewed papers with key insights into the molecular epidemiology of human papillomaviruses (HPV) in cervical precancer and cancer. She has overseen a number of large-scale multidisciplinary population-based projects in cervical cancer, including pivotal work in HPV screening and HPV vaccines. Dr Wheeler was the Principal Investigator for both the Merck Gardasil and GSK Cervarix phase III efficacy studies whilst the Wheeler clinical trials group acted as the lead enrolment site for North America.

In clinical aspects of HPV research, she was an early proponent of the viral etiology of cervical cancer. Her studies of viruses in cervical lesions spawned several DNA-based HPV diagnostics. Her epidemiological research of cervical disease also helped identify host, as well as viral, risk factors of cervical disease.

Cosette has been a contributor in several large multi-site studies that have shaped public opinion and policy in cervical cancer public health. From the late 1990s until 2003, she was heavily involved with the US National Cancer Institute's ASCUS-LSIL Triage Study (ALTS).

The Wheeler laboratory in Albuquerque, the Interdisciplinary Center for HPV Prevention ([ICHP](#)), is one of only five National Institute of Allergy and Infectious Diseases Cooperative Research Centers for Sexually Transmitted Diseases ([STI-CRC](#)). The ICHP is further supported by the National Cancer

Institute as a Population-based unique Research Optimizing Screening through Personalized Regimens ([PROSPR](#)) center. The PROSPR scheme has funded the development of a new and exciting approach to HPV monitoring with the establishment of the New Mexico HPV Outcomes, Practice Effectiveness and Surveillance Center ([NM-HOPES](#)). This center, under Cosette's leadership, is a unique state-wide resource that captures all Pap and HPV tests, as well as all cervical, vulvar, and vaginal pathology and links these results to all treatments and outcomes via the New Mexico HPV Registry.

In 2006 Dr. Wheeler was presented the American Society of Colposcopy and Cervical Pathology (ASCCP) Distinguished Scientific Achievement Award. She has served as a Research Associate for the US National Research Council and as a scientific fellow for both the US National Science Foundation and the American Social Health Association. Cosette has acted as an advisor to the WHO, the US Centers for Disease Control, the Indian Health Service, the American Cancer Society, the International Agency for Research on Cancer (IARC), Cancer UK, and the Instituto Nacional de Salud Publica (Guernevaca, Mexico).

Professor Suzanne Garland MBBS MD FRCPA FRANZCOG Ad Eundem FACHSHM

Professor Suzanne Garland is an internationally-recognised clinical microbiologist and sexual health physician, with particular expertise in infectious diseases relating to reproductive health and infants.

After completing her Bachelor of Medicine at the University of Melbourne in 1971, she worked overseas for a year as a Research Fellow at Harvard University in Boston. She started as Director of Clinical Microbiology and Infectious Diseases at the Royal Women's Hospital in 1984. Recognised for her research on infectious diseases, particularly in women's and newborn health,

Professor Garland is a regular advisor to the World Health Organisation on sexual and reproductive health infections, cervical cancer and human papillomavirus (HPV). Her team were leaders in the role of patient self-collected genital sampling in the detection by molecular techniques of reproductive tract infections, eg Chlamydia trachomatis, Neisseria gonorrhoeae, Trichomonas vaginalis, herpes simplex virus and HPV.

Professor Garland has been a chief investigator for phase III, clinical HPV vaccine trials for both Merck's Gardasil and GSK's Cervarix vaccines and is currently measuring vaccine effectiveness post the vaccine rollout in Australia and she has been involved with the role of HPV in cancers and precursor lesions (CIN3). Her laboratory is the Western Pacific Regional reference laboratory of the HPV Labnet, established by the World Health Organization (WHO).

Professor Garland was integral to the establishment 10 years ago of the Asian-Oceania Research Organisation on Genital Infection and Neoplasia (AOGIN), which brings together clinicians and scientists in the region whose work is related to genital infections and neoplasia. She was the inaugural and past president of the organisation and remains an ongoing board advisor.

Holding an Honorary Research Fellow position at Murdoch Children's Research Institute, and Professional chair through the Department of Obstetrics and Gynaecology at the University of Melbourne, Professor Garland is a Fellow at the Faculty of Science at the Royal College of Pathologists of Australasia (RCPA) and of Australian Society for Microbiology (FASM) plus RANZCOG Ad Eundem.

Associate Professor Sepehr Tabrizi BS, MS, Ph.D.

Associate Professor Sepehr Tabrizi received his PhD from the University of Melbourne in 1990 and has worked in the field of human papillomavirus (HPV) research for more than 20 years. He is a molecular microbiologist with a strong focus on using molecular tools for better understanding disease transmission and epidemiology of sexually transmitted infections (STIs) as well as clinical translation of research findings which has led to improvements in the diagnosis, management and prevention of STIs. He is a fellow of the Faculty of Science, The Royal College of Pathologists of Australasia; FFSc (RCPA) and the Australian Society for Microbiology (FASM).

For further information please contact:

Mr Richard Hannebery
Chief Executive Officer
Genera Biosystems Limited
Telephone: +61 (0)3 9763 1287
www.generabiosystems.com.au

About Genera Biosystems: Genera Biosystems Limited (“GBI”) is an Australian Stock Exchange listed molecular diagnostics company, which develops, manufactures and distributes advanced PCR molecular diagnostics tests. GBI has successfully developed two products to date, PapType® and RTI-Plex™, both of which are CE-IVD approved with several additional products in the company’s development pipeline. Genera manufactures these products in its Therapeutics Goods Administration (TGA) certified manufacturing facility in Scoresby, Victoria, Australia.